Tesofensine/AOD-9604

The Tesofensine / AOD-9604 Blend delivers a dual-action research compound designed to target multiple metabolic pathways associated with weight regulation, fat loss, and energy balance. Tesofensine is a triple monoamine reuptake inhibitor studied for its ability to reduce appetite and increase energy levels by enhancing dopaminergic, serotonergic, and noradrenergic activity. AOD-9604, a modified peptide fragment of human growth hormone, has been shown in preclinical studies to stimulate lipolysis and inhibit lipogenesis without affecting insulin or IGF-1 levels.

This combination is designed to explore central appetite suppression alongside peripheral fat metabolism, offering a comprehensive approach to weight management research.

How the Tesofensine / AOD-9604 Blend Works (Based on Preclinical Research):

• Tesofensine: Inhibits reuptake of dopamine, norepinephrine, and serotonin to reduce appetite and increase energy

• AOD-9604: Mimics the fat-burning region of HGH to stimulate lipolysis and prevent new fat accumulation

• Synergistic action may result in reduced caloric intake and enhanced fat oxidation

• Suitable for research models of obesity, metabolic syndrome, and body recomposition

Potential Benefits (Based on Preclinical Research):

• Appetite suppression with enhanced satiety signaling

• Increased fat breakdown and metabolic rate

• Reduced visceral and subcutaneous fat mass

• Improved energy balance without significant hormonal disruption

⚠️ For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory body and is intended solely for laboratory research.